Navigation Links
Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
Date:4/23/2008

G, Inc., is funding the clinical trial under a collaborative agreement with Vical.

The AIMM trial calls for enrollment of approximately 375 patients with Stage III or IV metastatic melanoma. Patients may have been previously treated with surgery, adjuvant therapy, and/or biotherapy, but cannot have been previously treated with cytotoxic chemotherapy. The patients will be randomized on a 2:1 basis: approximately 250 patients will be treated with Allovectin-7(R) and approximately 125 will be treated with their physician's choice of either of two chemotherapy agents, dacarbazine or temozolomide. The primary endpoint is a variation of progression-free survival, specifically comparison of objective response rates at six months or more after randomization. The study will also evaluate safety and tolerability as well as overall survival. A patient self-screening tool for trial eligibility is available online at http://www.melanomaclinicaltrial.com.

About Metastatic Melanoma

The American Cancer Society has estimated that more than 62,000 new diagnoses of, and approximately 8,400 deaths from, melanoma will occur in 2008 in the United States. Currently, there are no consistently effective therapies for advanced cases of metastatic melanoma where the cancer has spread to other parts of the body. The toxicity associated with FDA-approved treatments such as dacarbazine or interleukin-2 is often significant, resulting in serious or life-threatening side effects in many of the patients treated. Patients with metastatic melanoma often are treated off-label with drugs such as temozolomide, which has been approved by the FDA for the treatment of certain types of brain cancer but not for the treatment of metastatic melanoma. Temozolomide is an orally-delivered pro-drug that converts in the body into the same active compound as dacarbazine.

About Vical

Vical researches and develops bioph
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
2. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
3. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
4. Spine Institute of Louisiana Offers Cervical Spine Motion Preservation as an Alternative to Fusion Surgery
5. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
8. New Study Shows Listeria Vaccine for Cervical Cancer Found Safe
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- ... affects persons of all ages, but most commonly ... condition characterized by narrowing of the airways, leading ... the lungs come into contact with endogenous and ... of events, such as swelling of the airways, ...
(Date:9/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... owned subsidiary, Valeant Pharmaceuticals International, will redeem all of ... 6.75% Senior Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 ... has mailed an irrevocable notice of redemption for the ... of the irrevocable notice of redemption with respect to ...
(Date:9/15/2014)... , Sept. 15, 2014  Decision Resources ... Physician™ 2014, finds that online information and ... brands to differentiate their offering and support ... device purchasing decisions rely on websites, mobile ... about devices—and these physicians are looking to ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2Physician device decision-makers show strong demand for device manufacturer digital content and support 2Physician device decision-makers show strong demand for device manufacturer digital content and support 3
... A recently published University of Nevada study indicates that ... the air to reduce the impact of oxidation on essential ... the study showed similar impacts on Vitamin C.   ... human milk and infant formula using varied bottle systems ," ...
... LA JOLLA, Calif., Dec. 13, 2010 Anaphore ... into a partnership with Mitsubishi Tanabe Pharma Corporation (Osaka, ... novel protein therapies for autoimmune disease . ... platform technology, which generates novel trivalent proteins called ...
Cached Medicine Technology:Published Study Concludes: Vented Baby Bottles Protect Essential Nutrients in Breast Milk and Formula 2Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 2Anaphore Enters R&D Partnership with Mitsubishi Tanabe Pharma to Develop and Commercialize Novel Protein Pharmaceuticals for Autoimmune Disorders 3
(Date:9/16/2014)... Hills, CA (PRWEB) September 16, 2014 ... announce the launch of ACLsurgeryLA.com , a specialty ... ACL injuries. As an avid sports lover and ... options for treatment and recovery from injuries to maintain ... opportunity to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... NY (PRWEB) September 16, 2014 Registration ... Run For The Warriors®, a 10K, 5K, and 1-mile ... The race is sponsored by Local 338 RWDSU/UFCW, the ... will begin at the Town of Babylon Town Hall ... http://www.hopeforthewarriors.org/2014LIRun . The run is organized by Hope ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 *To find out ... visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ) ... who qualify:, There is no cost ... , Compensation may be provided for time and ... and influenza are the eighth leading cause of death in ...
(Date:9/16/2014)... DeLand, Florida (PRWEB) September 16, 2014 ... clinical trials being conducted in DeLand, FL can visit ... or contact them directly at (386) 785-2404. , Why ... of the most widespread viral diseases infecting mankind. While ... past, these colds still account for more annual visits ...
(Date:9/16/2014)... 2014 justthoughtyoushouldknow.org , popular ... launches their new site today. The new site ... at making information easier to find, ingest, and ... into one-page, easy-to-read pages the information that we ... Virginia Downie, retired college professor and founder of ...
Breaking Medicine News(10 mins):Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2
... Dec. 6 Arete Therapeutics Inc., a,privately-held biopharmaceutical ... of cardiovascular, inflammatory and,metabolic diseases, today announced the ... directors., "We are very pleased to welcome ... and operational insights will be of great benefit ...
... Name Also Unveiled in Ongoing Preparation for ... Favrille, Inc. (Nasdaq:,FVRL), a biopharmaceutical company ... cancer, announced that new data,including four-year follow-up ... of Specifid(TM) (formerly FavId(R)), will be reported ...
... Oncology, the nation,s leading,oncology services company, today named ... and chief operating officer. The appointment,becomes effective on ... experience, combined with his work in,large diversified healthcare ... Broussard, president of US Oncology.,"His proven success in ...
... first increase in U.S.,teen pregnancy rates, WASHINGTON, Dec. ... pregnancy rates in the United States over the,last fourteen ... should not come as a surprise since the dual ... -- the decline in sexual,initiation and more effective use ...
... http://feeds.feedburner.com/OrthoWomensHealthAndUrology , RARITAN, NJ, December 5 Jane ... about the Pill as part of The Modern,Girl,s Guide ... Girl,s Guide to the Pill, When: The Podcast ... Where: http://feeds.feedburner.com/OrthoWomensHealthAndUrology , How: Go to ...
... With the popularity of,fillers becoming mainstream, it,s no ... prevent facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic ... "Fillers such as Artefill, Radiesse and Sculptra contain ... tissue, all of,these products can cause foreign body ...
Cached Medicine News:Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 2Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 3Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 4Health News:Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting 5Health News:US Oncology Appoints Glen Laschober EVP & Chief Operating Officer 2Health News:Facial Deformity Danger? 2
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With reinforced ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
Medicine Products: